摘要
目的探讨清养活血2号方治疗老年急性缺血性卒中相关性肺炎(SAP)气虚痰热瘀阻证的临床效果。方法选择2021年2月至2022年12月重庆市中医院收治的老年急性缺血性SAP气虚痰热瘀阻证患者66例,采用随机数字表法将其分为观察组(33例)和对照组(33例)。对照组给予规范化治疗,观察组在对照组基础上给予清养活血2号方。治疗10 d后比较两组临床效果,比较两组在治疗前及治疗第5、10天的中医证候积分、美国国立卫生研究院卒中量表评分(NIHSS)、急性生理和慢性健康状况Ⅱ(APACHEⅡ)评分、临床肺部感染评分(CPIS)、全身炎症反应综合征(SIRS)评分、血清降钙素原(PCT)水平。统计两组治疗期间不良反应发生情况。结果观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。两组治疗第5、10天中医证候积分、血清PCT水平、NIHSS、APACHEⅡ评分、SIRS、CPIS均低于治疗前,且治疗第10天低于治疗第5天,差异有统计学意义(P<0.05)。观察组治疗第5、10天中医证候积分及APACHEⅡ评分、SIRS均低于同期对照组,观察组治疗第10天NIHSS、CPIS、血清PCT水平均低于同期对照组,差异有统计学意义(P<0.05)。两组均未发生明确药物过敏、皮肤、药物性肝肾损害及其他不良反应。结论清养活血2号方能够改善老年急性缺血性SAP患者的中医证候,提高整体疗效,安全性较好。
Objective To investigate the clinical effect of Qingyang Huoxue No.2 Prescription on acute ischemic stroke associated pneumonia(SAP)in the elderly with the syndrome of qi deficiency,phlegm-heat stasis,and obstruction.Methods Sixty-six elderly patients with acute ischemic SAP with the syndrome of qi deficiency,phlegm-heat stasis,and obstruction admitted to Chongqing Hospital of Traditional Chinese Medicine from February 2021 to December 2022 were selected and divided into observation group(33 cases)and control group(33 cases)by random number table method.The control group was given standardized treatment,and the observation group was given Qingyang Huoxue No.2 Prescription based on the control group.After ten days of treatment,the clinical effect of the two groups was compared.Chinese medicine syndrome score,National Institutes of Health stroke scale score(NIHSS),acute physiology and chronic health evaluation-Ⅱ(APACHEⅡ)score,clinical pulmonary infection score(CPIS),systemic inflammatory response syndrome(SIRS)score,and serum procalcitonin(PCT)levels were compared between the two groups before treatment and the fifth,tenth day of treatment.The incidence of adverse reactions in the two groups during treatment was analyzed.Results The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).Chinese medicine syndrome score,serum PCT level,NIHSS,APACHEⅡscore,SIRS,CPIS in two groups at the fifth,and tenth day of treatment were lower than those before treatment,and those at the tenth day of treatment were lower than those at five days after treatment,the differences were statistically significant(P<0.05).Chinese medicine syndrome scores,APACHEⅡscore,SIRS in the observation group at the fifth and tenth day of treatment were lower than those in the control group at the same period,and NIHSS,CPIS,and serum PCT level in the observation group at the tenth day of treatment were lower than those in the control group at the same period,the differences were statistically significant(P<0.05).No drug allergy,skin,drug-induced liver,and kidney damage or other adverse reactions occurred in the two groups during treatment.Conclusion Qingyang Huoxue No.2 Prescription can improve the Chinese medicine syndrome of elderly patients with acute ischemic SAP,improve the overall curative effect,and have good safety.
作者
朱建伟
唐国华
陶文强
ZHU Jianwei;TANG Guohua;TAO Wenqiang(Department of Encephalopathy,Chongqing Hospital of Traditional Chinese Medicine,Chongqing 400021,China)
出处
《中国医药导报》
CAS
2024年第1期131-135,共5页
China Medical Herald
基金
重庆市自然科学基金面上项目(cstc2020jcyj-msxmX0011)
重庆市科卫联合中医药技术创新与应用发展项目(2020ZY023533、2021ZY023596)。
关键词
清养活血2号方
卒中相关性肺炎
老年
气虚痰热瘀阻证
Qingyang Huoxue No.2 Prescription
Stroke associated pneumonia
Elderly
Syndrome of qi deficiency,phlegm-heat stasis,and obstruction
